The use of novel targeted anticancer agents has led to overall improvement in the prognosis
of many patients affected by various malignancies, but has also been associated with an …

The introduction of novel targeted therapies during the last 2 decades has led to a significant
improvement in patients' clinical outcomes with renal cell carcinoma. However, this …

Aims: Sine efficiency of tyrosine kinase inhibitor (TKI) therapy in dialyzed patients is still
unclear we aim to analyze the outcome of treatment in such cohort. Patients & methods: We …

Background Patients with severe renal impairment or undergoing hemodialysis are usually
excluded from clinical trials. Available data regarding safety and activity of systemic …

Purpose Everolimus has demonstrated its efficacy in metastatic renal cell carcinoma
(mRCC). Preliminary studies have shown high variability of everolimus blood concentrations …

The increasing availability of novel biological anticancer agents has greatly improved the
outcome of several cancer patients; unfortunately, data regarding efficacy, safety and …

Background Renal cell carcinoma (RCC) may involve both kidneys. When bilateral
nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients …

We retrospectively identified patients with end‐stage renal disease undergoing
hemodialysis treated with the mammalian target of rapamycin inhibitors as a second‐and/or …

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with
metastatic renal cell carcinoma. Besides, mammalian target of rapamycin inhibition has the …

Aims: This retrospective study aimed to investigate safety and efficacy of everolimus in
patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring …